SCHEMBL2901475

SCHEMBL2901475

Cc1ccc(C(C)Nc2ccc3c(NS(=O)(=O)c4cc(F)cc(F)c4)cccc3n2)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
CLK1 P49759 1/20 0.34
BRD4 O60885 2/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
PKM P14618 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 2/20 0.33
ALOX15 P16050 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MAPK1 P28482 2/20 0.33
S1PR4 O95977 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
S1PR1 P21453 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901736 0.81 L3MBTL1 (0.40) L3MBTL1GAAMAPTCLK1KMT2A
SCHEMBL3951739 0.80 L3MBTL1 (0.39) L3MBTL1GAAMAPTCLK1BRD4
SCHEMBL2905387 0.78 RECQL (0.39) L3MBTL1GAAMAPTCLK1KMT2A
SCHEMBL2906872 0.75 SLC10A2 (0.45) L3MBTL1MAPTKMT2AMEN1HTT
SCHEMBL2904287 0.75 L3MBTL1 (0.48) L3MBTL1GAAMAPTCLK1BRD4
SCHEMBL3951736 0.75 L3MBTL1 (0.38) L3MBTL1GAAMAPTCLK1BRD4
SCHEMBL2901907 0.74 SMN1; SMN2 (0.42) L3MBTL1GAAMAPTCLK1KMT2A
SCHEMBL2907742 0.74 RECQL (0.53) L3MBTL1GAAMAPTCLK1KMT2A
SCHEMBL2907020 0.73 SLC40A1 (0.49) GAAMAPTCLK1KMT2AMEN1
SCHEMBL2902345 0.72 EPHB4 (0.47) GAAMAPTCLK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US claimed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP claimed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US claimed
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 L3MBTL1 3963/4885GAA 3960/4885MAPT 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.